Minimal Residual Disease Testing: Current Innovations And Future Directions by Todd E. DruleyMinimal Residual Disease Testing: Current Innovations And Future Directions by Todd E. Druley

Minimal Residual Disease Testing: Current Innovations And Future Directions

byTodd E. Druley

Paperback | November 27, 2018

Pricing and Purchase Info

$105.75 online 
$120.95 list price save 12%
Earn 529 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. 

Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice.

Todd E. Druley, MD, PhDAssociate Professor of Pediatrics, Genetics and Developmental BiologyDirector, Fellowship Program in Pediatric Hematology and OncologyDirector, Pediatric Cancer Predisposition ProgramWashington University in St. LouisDepartment of PediatricsDivision of Hematology and OncologyCenter for Genome Sciences and Systems...
Title:Minimal Residual Disease Testing: Current Innovations And Future DirectionsFormat:PaperbackDimensions:197 pagesPublished:November 27, 2018Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3319948261

ISBN - 13:9783319948263


Table of Contents

1. Introduction
Nitin Mahajan, Todd Druley

2. Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/Lymphoma
Laura Wake, Xueyan Chen, Michael J. Borowitz 

3. Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies
Barbara K. Zehentner

4. Monitoring AML Response Using "Difference From Normal" Flow Cytometry
Michael R. Loken, Lisa Eidenschink Brodersen, Denise A. Wells

5. ML-DS: A Unique Condition for Measurable Residual Disease Detection 
Elisabeth R. Wilson, R. Spencer Tong

6. Advancements in Next Generation Sequencing for Detecting Minimal Residual Disease
Erin L. Crowgey, Nitin Mahajan